Earnings Releases·Nov 2, 2026, 4:04 PM ET

Tactile Systems Technology — Third Quarter 2026 Earnings Summary

Total revenue rose 7% year-over-year to $91.9 million in Q3 2026, driven by a 13% increase in the lymphedema segment, while airway clearance revenue fell 25% due to inventory transitions; gross margin expanded to 77% and nine-month net income surged 56% to $13.2 million.
Full-year 2026 Adjusted EBITDA guidance was raised to $50–$52 million from the prior $49–$51 million range, with total revenue guidance maintained at $360–$366 million.
The company repurchased $6.2 million of stock in the quarter, leaving $12.5 million available under its $25 million program, while operating expenses increased 13% to $60.9 million to fund long-term growth initiatives.
Strategic progress includes FDA 510(k) clearance for the LymphaTech 3D Scanner, a submitted application for the Flexitouch® Pro, and the appointment of Steve Kiewiet as Chief Operating Officer.